Osiris Therapeutics, Inc.
Osiris Therapeutics, Inc., having developed the world’s first approved stem cell drug, Prochymal®, is the leading stem cell company. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. Osiris‘ Biosurgery segment seeks to harness the ability of cells and novel constructs to promote the body's natural healing, with the goals of improving surgical outcomes and offering better treatment options for patients and physicians. Osiris currently markets and sells Grafix® and Ovation® for tissue repair. The Company’s Therapeutics segment is focused on developing biologic stem cell drug candidates from a readily available and non-controversial source - adult bone marrow. The Company‘s lead biologic drug candidate, Prochymal (remestemcel-L), is approved in Canada and New Zealand for the management of acute graft-versus-host disease (GvHD) in children and is available for adults and children in eight countries including the United States, under an Expanded Access Program. Prochymal is currently in Phase 3 trials for refractory Crohn’s disease and is also being evaluated in clinical trials for the treatment of myocardial infarction (heart attack) and type 1 diabetes. Osiris’ stem cell products have significant therapeutic potential because of their ability to regulate inflammation, promote tissue regeneration and prevent scar formation.
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.
The goal of Myriad is to make a difference in patient’s lives and for the past twenty years, the Company’s strategy has been guided by this mission. To accomplish this, Myriad is focused on revolutionizing patient care through the development and marketing of transformative tests which address pressing clinical needs across multiple medical specialties.
Over the last twenty years, Myriad has invested heavily in the education of patients and health care providers on the role genes and their related proteins play in disease. Almost one million patients have already benefited from Myriad’s informative testing, which helps physicians better manage their health care.
Today, Myriad continues to build on this strong tradition. It is working to expand its reach by introducing newgenetic tests and molecular diagnostic tests for a number of diseases. The Company is also focused on extending our mission internationally, in an effort to broaden our geographic footprint and provide critical information to more patients and healthcare providers.
Prolexys Pharmaceuticals, Inc. was founded in 2001 with a focus to develop innovative small molecules for the treatment of cancer. Prolexys’ primary drug candidate, PRLX 93936 is a first-in-class multi-phosphatase inhibitor, currently in development for patients with refractory multiple myeloma. PRLX 93936 is active in vitro and in vivo against a broad range of multiple myeloma cell lines, many with Ras pathway activation. In 2011, a research collaboration between Prolexys and the Dana Farber Cancer Institute demonstrated efficacy and survival improvement in a mouse study of multiple myeloma.
ETEX Corporation has developed, manufactured and marketed proprietary, nanocrystalline calcium-phosphate-based biomaterials that promote the repair and regeneration of bone damaged by trauma or disease. Our experience and expertise in bone biology and biomaterials is the foundation for a robust, innovative, market-driven product pipeline. The current product portfolio of synthetic calcium phosphate based bone substitute materials is rapidly expanding via the accelerated development of versatile carrier technologies and osteoinductive combination products.
mPortal Inc enables the creation of connected experiences for content and applications (video, music, apps and web) across mobile, tablet and connected TVs. The Company provides a cloud-based platform that is an end-to-end solution for the discovery and delivery of various apps and services.
The Company has been profitable for the past three years and has made tremendous inroads into both the mobile operator and cable operator space in North America. It is well positioned to accelerate its reach and growth based on its current products and services and is also actively looking to expand its scale and scope by working with third party channels and distributors.
The Company’s flagship product, SPRINGBOARDTM is a cloud based platform that has been built over several years and has the capability to handle millions of users and end devices as well as the ability to integrate to third party billing, authentication, app store and content systems at mobile, cable and media companies.